Sensus Healthcare, Inc. (NASDAQ:SRTS) Shares Sold by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC cut its holdings in Sensus Healthcare, Inc. (NASDAQ:SRTSGet Rating) by 10.0% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 40,576 shares of the company’s stock after selling 4,500 shares during the period. Janney Montgomery Scott LLC’s holdings in Sensus Healthcare were worth $508,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Bailard Inc. boosted its position in shares of Sensus Healthcare by 3.9% during the second quarter. Bailard Inc. now owns 34,600 shares of the company’s stock worth $266,000 after buying an additional 1,300 shares during the period. Northern Trust Corp boosted its position in Sensus Healthcare by 15.0% during the 1st quarter. Northern Trust Corp now owns 24,602 shares of the company’s stock worth $249,000 after acquiring an additional 3,203 shares during the period. Denali Advisors LLC bought a new position in shares of Sensus Healthcare in the third quarter worth $46,000. State Street Corp increased its holdings in shares of Sensus Healthcare by 8.9% during the first quarter. State Street Corp now owns 46,052 shares of the company’s stock valued at $466,000 after purchasing an additional 3,765 shares during the period. Finally, Jane Street Group LLC raised its stake in shares of Sensus Healthcare by 29.9% during the second quarter. Jane Street Group LLC now owns 17,167 shares of the company’s stock valued at $132,000 after purchasing an additional 3,948 shares in the last quarter. 36.25% of the stock is owned by institutional investors and hedge funds.

Sensus Healthcare Stock Up 4.6 %

Shares of SRTS stock opened at $9.15 on Monday. The stock has a 50-day simple moving average of $7.20 and a 200 day simple moving average of $10.30. Sensus Healthcare, Inc. has a fifty-two week low of $5.58 and a fifty-two week high of $15.25. The stock has a market capitalization of $152.00 million, a P/E ratio of 5.68 and a beta of 0.55.

Sensus Healthcare (NASDAQ:SRTSGet Rating) last issued its quarterly earnings results on Thursday, November 3rd. The company reported $0.11 earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.01). Sensus Healthcare had a net margin of 60.14% and a return on equity of 34.75%. The business had revenue of $9.01 million during the quarter, compared to analyst estimates of $8.92 million. On average, sell-side analysts anticipate that Sensus Healthcare, Inc. will post 0.79 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently issued reports on SRTS. TheStreet lowered shares of Sensus Healthcare from a “b” rating to a “c+” rating in a research report on Friday, November 4th. Alliance Global Partners lowered their price objective on shares of Sensus Healthcare from $17.50 to $16.50 and set a “buy” rating on the stock in a research note on Friday, November 4th.

Sensus Healthcare Profile

(Get Rating)

Sensus Healthcare, Inc operates as a medical device company, which provides treatments for both oncological and non-oncological skin conditions. The firm’s portfolio of treatment devices includes the SRT-100, SRT-100+, and SRT-100 Vision. Its main product superficial radiation therapy (SRT), a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating basal cell and squamous cell skin cancers, and other skin conditions, such as keloids.

Featured Articles

Want to see what other hedge funds are holding SRTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sensus Healthcare, Inc. (NASDAQ:SRTSGet Rating).

Institutional Ownership by Quarter for Sensus Healthcare (NASDAQ:SRTS)

Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.